CannaTech: Sydney--World's Top Medical Cannabis Scientists and Business Leaders to Gather at Australia's First Ever Medical Cannabis Conference October 28- 30
Medical cannabis spending in Australia to grow to $1.2 billion in 2027
Worldwide, medical cannabis spending will reach $19.1 billion by 2027
91% of Australians Support Medical Cannabis Use
TEL AVIV, Israel, Oct. 2, 2018 /PRNewswire/ -- The world's leading cannabis researchers and scientists, ag-tech, pharma experts, regulators, investors, and entrepreneurs will share their knowledge about the burgeoning medical cannabis industry at CannaTech Sydney, Australia's first-ever international Summit for Accelerating Medical Cannabis Innovation.
The main event will take place October 29-30 at Doltone House, Darling Island. The summit will be preceded on October 28 by a special Cannabis Business Symposium.
The cannabis economy is the world's fastest growing industry, with an outstanding record of accomplishment in research and development and with significant contribution to a vast array of medical treatments.
Economists foresee the potential overall cannabis and cannabis-related product market reaching tens of billions of dollars in the next decade. According to The Arcview Group, medical cannabis spending in Australia is expected to grow from $52 million in 2018 to $1.2 billion in 2027. Worldwide, medical cannabis spending will reach $19.1 billion worldwide by 2027.
Companies, entrepreneurs, researchers, investors, and other stakeholders will meet at CannTech Sydney to connect and learn about opportunities in the booming medical cannabis market as well as the latest technologies and research in the field and the latest global regulatory developments.
CannaTech Sydney attendees will hear from and meet the industry's most serious thought leaders and market disruptors from around the world as well as Australian parents and patients who rely on medical cannabis for the well being of their children and themselves.
The Summit will cover the most current industry topics including Ag Tech & Innovation, Business & Finance, Policy & Regulation, Science & Medicine.
Australian companies in the forefront of the industry are sponsors of the event including, MGC Pharma, Spectrum, CannaGroup, AusCann, MediFarm, Canngea, Little Green Pharma, Cresco, Everblue Capital, CannaTrek, Nutrition Care, BOD Australia, BioCeuticals, WHG. They join world-wide industry leaders New Frontier and Tilray.
Explaining why CannaTech has chosen Sydney for their next event, Saul Kaye, Founder & CEO of iCAN:Israel-Cannabis and CannaTech said, "Australia is a key and growing player in the exploding cannabis field. Many Australian cannabis companies are on the cutting edge of the market and we are thrilled to bring some of the world's leading companies and investors to Australia to meet with their counterparts to discuss a range of business and technological issues.
"Mothers and citizens of all stripes are outraged over the lack of easy access to products for epilepsy, pain, and cancer treatments. As we have seen in other countries this is one of the biggest drivers towards better access for patients. In fact, surveys indicate that 91% of Australians favour medical cannabis use." As a native Aussie myself, I could not be prouder to bring CannaTech to my home country and work with like-minded professionals who understand the immense global health and business potential of medical cannabis moving forward."
About iCAN: Israel-Cannabis
iCAN is building the global cannabis ecosystem. iCAN identifies and accelerates innovative medical cannabis technologies and creates synergies and cooperation across the industry. iCAN uses its global network and reach to position Israel as the leading medical cannabis tech hub.
BDA Price at posting:
64.0¢ Sentiment: Hold Disclosure: Held
